
Chinese General Practice ›› 2024, Vol. 27 ›› Issue (22): 2724-2730.DOI: 10.12114/j.issn.1007-9572.2023.0661
Special Issue: 肿瘤最新文章合辑; 消化系统疾病最新文章合辑
• Article • Previous Articles Next Articles
Received:2023-10-25
Revised:2023-12-26
Published:2024-08-05
Online:2024-05-28
Contact:
YU Dehua
通讯作者:
于德华
作者简介:作者贡献:
杨森、葛许华、于德华提出主要研究目标,负责研究的构思与设计;杨森负责研究的实施,撰写并修订论文;赵华新、马乐、金花、谢木金、普珍、白朝辉进行数据的收集与整理,统计学处理,图、表的绘制与展示;于德华负责文章的质量控制与审查,对文章整体负责,监督管理。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0661
| 组别 | 例数 | 性别(男/女) | 年龄[M(P25,P75),岁] | 合并慢性病情况[例(%)] | 病变部位[例(%)] | 肿瘤TNM分期[例(%)] | 病理类型[例(%)] | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 高血压 | 糖尿病 | 冠心病 | 慢性支气管炎 | 结肠 | 直肠 | Ⅰ~Ⅱ期 | Ⅲ~Ⅳ期 | 管状腺癌 | 黏液腺癌 | 其他类型 | ||||
| 对照组 | 40 | 18/22 | 67(60,70) | 30(75.0) | 16(40.0) | 7(17.5) | 6(15.0) | 26(65.0) | 14(35.0) | 22(55.0) | 18(45.0) | 33(82.5) | 4(10.0) | 3(7.5) |
| 联合管理组 | 36 | 20/16 | 66(61,71) | 28(77.8) | 18(50.0) | 6(16.7) | 5(13.9) | 23(63.9) | 13(36.1) | 19(52.8) | 17(47.2) | 31(86.1) | 3(8.3) | 2(5.6) |
| χ2(Z)值 | 0.844 | -0.451a | 0.081 | 0.766 | 0.009 | 0.019 | 0.010 | 0.038 | 0.195 | |||||
| P值 | 0.358 | 0.652 | 0.776 | 0.381 | 0.923 | 0.891 | 0.920 | 0.846 | 0.907 | |||||
| 组别 | 手术方式[例(%)] | 化疗方式[例(%)] | ||||||||||||
| 结肠癌根治性手术 | 结肠癌并发急性梗阻手术 | 直肠癌局部切除术 | 姑息手术 | 辅助化疗 | FOLFOX方案 | CAPEOX方案 | 新辅助化疗 | 靶向治疗 | 免疫治疗 | |||||
| 对照组 | 23(57.5) | 3(7.5) | 2(11.9) | 2(5.0) | 36(90.0) | 19(47.5) | 17(42.5) | 5(11.9) | 3(7.1) | 2(4.8) | ||||
| 联合管理组 | 22(61.1) | 2(5.6) | 1(10.0) | 3(8.3) | 33(91.7) | 21(58.3) | 12(33.3) | 6(15.0) | 2(5.0) | 1(5.0) | ||||
| χ2(Z)值 | 0.102 | 0.015 | 0.009 | 0.015 | 0.021 | 0.892 | 0.675 | 0.266 | 0.015 | 0.009 | ||||
| P值 | 0.749 | 0.903 | 0.926 | 0.903 | 0.884 | 0.345 | 0.411 | 0.606 | 0.903 | 0.926 | ||||
Table 1 Comparison of general information between two groups of patients after colorectal cancer surgery
| 组别 | 例数 | 性别(男/女) | 年龄[M(P25,P75),岁] | 合并慢性病情况[例(%)] | 病变部位[例(%)] | 肿瘤TNM分期[例(%)] | 病理类型[例(%)] | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 高血压 | 糖尿病 | 冠心病 | 慢性支气管炎 | 结肠 | 直肠 | Ⅰ~Ⅱ期 | Ⅲ~Ⅳ期 | 管状腺癌 | 黏液腺癌 | 其他类型 | ||||
| 对照组 | 40 | 18/22 | 67(60,70) | 30(75.0) | 16(40.0) | 7(17.5) | 6(15.0) | 26(65.0) | 14(35.0) | 22(55.0) | 18(45.0) | 33(82.5) | 4(10.0) | 3(7.5) |
| 联合管理组 | 36 | 20/16 | 66(61,71) | 28(77.8) | 18(50.0) | 6(16.7) | 5(13.9) | 23(63.9) | 13(36.1) | 19(52.8) | 17(47.2) | 31(86.1) | 3(8.3) | 2(5.6) |
| χ2(Z)值 | 0.844 | -0.451a | 0.081 | 0.766 | 0.009 | 0.019 | 0.010 | 0.038 | 0.195 | |||||
| P值 | 0.358 | 0.652 | 0.776 | 0.381 | 0.923 | 0.891 | 0.920 | 0.846 | 0.907 | |||||
| 组别 | 手术方式[例(%)] | 化疗方式[例(%)] | ||||||||||||
| 结肠癌根治性手术 | 结肠癌并发急性梗阻手术 | 直肠癌局部切除术 | 姑息手术 | 辅助化疗 | FOLFOX方案 | CAPEOX方案 | 新辅助化疗 | 靶向治疗 | 免疫治疗 | |||||
| 对照组 | 23(57.5) | 3(7.5) | 2(11.9) | 2(5.0) | 36(90.0) | 19(47.5) | 17(42.5) | 5(11.9) | 3(7.1) | 2(4.8) | ||||
| 联合管理组 | 22(61.1) | 2(5.6) | 1(10.0) | 3(8.3) | 33(91.7) | 21(58.3) | 12(33.3) | 6(15.0) | 2(5.0) | 1(5.0) | ||||
| χ2(Z)值 | 0.102 | 0.015 | 0.009 | 0.015 | 0.021 | 0.892 | 0.675 | 0.266 | 0.015 | 0.009 | ||||
| P值 | 0.749 | 0.903 | 0.926 | 0.903 | 0.884 | 0.345 | 0.411 | 0.606 | 0.903 | 0.926 | ||||
| 组别 | 例数 | 白细胞(×109/L) | 红细胞(×1012/L) | 血红蛋白(g/L) | 中性粒细胞百分比(%) | 丙氨酸氨基转移酶(U/L) | 天冬氨酸氨基转移酶(U/L) |
|---|---|---|---|---|---|---|---|
| 对照组 | 40 | 7.0(5.2,8.4) | 4.1(3.7,4.4) | 120.0(111.0,133.0) | 70.1(63.2,75.4) | 20.0(12.0,32.0) | 20.0(18.0,28.0) |
| 联合管理组 | 36 | 7.1(5.7,7.9) | 4.1(3.5,4.5) | 114.5(103.5,132.3) | 70.3(62.8,81.8) | 14.5(11.8,24.3) | 18.0(14.8,22.3) |
| Z值 | -0.479 | -0.169 | -0.795 | -0.068 | -1.714 | -1.693 | |
| P值 | 0.632 | 0.866 | 0.427 | 0.946 | 0.087 | 0.090 | |
| 组别 | 肌酐(µmol/L) | 尿素氮(mmol/L) | 癌胚抗原(ng/mL) | 血清CA199(U/mL) | 血清CA125(U/mL) | 血清CA724(U/mL) | |
| 对照组 | 61.0(55.0,72.0) | 6.0(4.3,8.2) | 2.3(1.4,5.7) | 9.8(5.5,16.1) | 8.7(6.4,13.2) | 1.7(0.7,5.2) | |
| 联合管理组 | 66.0(53.8,77.8) | 4.7(3.7,6.2) | 3.2(2.2,5.0) | 12.7(6.6,19.9) | 11.0(7.4,16.3) | 1.5(0.9,2.5) | |
| Z值 | -0.231 | -1.690 | -1.416 | -1.050 | -1.408 | -0.571 | |
| P值 | 0.817 | 0.091 | 0.157 | 0.294 | 0.159 | 0.568 |
Table 2 Comparison of preoperative laboratory indices between the two groups of colorectal cancer patients
| 组别 | 例数 | 白细胞(×109/L) | 红细胞(×1012/L) | 血红蛋白(g/L) | 中性粒细胞百分比(%) | 丙氨酸氨基转移酶(U/L) | 天冬氨酸氨基转移酶(U/L) |
|---|---|---|---|---|---|---|---|
| 对照组 | 40 | 7.0(5.2,8.4) | 4.1(3.7,4.4) | 120.0(111.0,133.0) | 70.1(63.2,75.4) | 20.0(12.0,32.0) | 20.0(18.0,28.0) |
| 联合管理组 | 36 | 7.1(5.7,7.9) | 4.1(3.5,4.5) | 114.5(103.5,132.3) | 70.3(62.8,81.8) | 14.5(11.8,24.3) | 18.0(14.8,22.3) |
| Z值 | -0.479 | -0.169 | -0.795 | -0.068 | -1.714 | -1.693 | |
| P值 | 0.632 | 0.866 | 0.427 | 0.946 | 0.087 | 0.090 | |
| 组别 | 肌酐(µmol/L) | 尿素氮(mmol/L) | 癌胚抗原(ng/mL) | 血清CA199(U/mL) | 血清CA125(U/mL) | 血清CA724(U/mL) | |
| 对照组 | 61.0(55.0,72.0) | 6.0(4.3,8.2) | 2.3(1.4,5.7) | 9.8(5.5,16.1) | 8.7(6.4,13.2) | 1.7(0.7,5.2) | |
| 联合管理组 | 66.0(53.8,77.8) | 4.7(3.7,6.2) | 3.2(2.2,5.0) | 12.7(6.6,19.9) | 11.0(7.4,16.3) | 1.5(0.9,2.5) | |
| Z值 | -0.231 | -1.690 | -1.416 | -1.050 | -1.408 | -0.571 | |
| P值 | 0.817 | 0.091 | 0.157 | 0.294 | 0.159 | 0.568 |
| 组别 | 例数 | 白细胞(×109/L) | 红细胞(×1012/L) | 血红蛋白(g/L) | 中性粒细胞百分比(%) | 丙氨酸氨基转移酶(U/L) | 天冬氨酸氨基转移酶(U/L) | 肌酐(µmol/L) |
|---|---|---|---|---|---|---|---|---|
| 对照组 | 40 | 4.7(4.0,6.0) | 3.7(3.5,4.1) | 120.5(115.8,129.3) | 62.5(52.4,76.2) | 27.0(15.8,62.5) | 40.0(22.8,55.0) | 65.0(58.3,76.8) |
| 联合管理组 | 36 | 7.0(5.8,8.2) | 4.0(3.8,4.3) | 125.0(114.0,134.0) | 66.8(53.4,84.7) | 20.0(13.3,23.5) | 24.5(20.5,29.0) | 66.0(50.8,75.3) |
| Z(χ2)值 | -1.623 | -1.606 | -1.015 | -0.783 | -0.490 | -0.812 | -0.214 | |
| P值 | 0.105 | 0.108 | 0.310 | 0.434 | 0.624 | 0.417 | 0.830 | |
| 组别 | 尿素氮(mmol/L) | 癌胚抗原(ng/mL) | 血清CA199(U/mL) | 血清CA125(U/mL) | 血清CA724(U/mL) | 复发转移患者数量[例(%)] | 并发症数量[例(%)] | |
| 对照组 | 5.7(4.6,6.6) | 3.2(2.6,4.7) | 17.6(7.8,30.5) | 9.9(6.3,12.1) | 2.2(0.6,5.1) | 3(7.5) | 6(16.2) | |
| 联合管理组 | 5.7(4.4,6.5) | 1.4(1.0,2.9) | 12.5(9.3,16.3) | 10.0(7.0,14.4) | 2.2(0.6,5.0) | 1(2.8) | 0 | |
| Z(χ2)值 | -0.058 | -4.653 | -1.595 | -0.271 | -0.145 | 0.165a | 3.981a | |
| P值 | 0.954 | <0.001 | 0.111 | 0.786 | 0.885 | 0.685 | 0.046 |
Table 3 Comparison between the two groups of colorectal cancer patients at 3 months after surgery
| 组别 | 例数 | 白细胞(×109/L) | 红细胞(×1012/L) | 血红蛋白(g/L) | 中性粒细胞百分比(%) | 丙氨酸氨基转移酶(U/L) | 天冬氨酸氨基转移酶(U/L) | 肌酐(µmol/L) |
|---|---|---|---|---|---|---|---|---|
| 对照组 | 40 | 4.7(4.0,6.0) | 3.7(3.5,4.1) | 120.5(115.8,129.3) | 62.5(52.4,76.2) | 27.0(15.8,62.5) | 40.0(22.8,55.0) | 65.0(58.3,76.8) |
| 联合管理组 | 36 | 7.0(5.8,8.2) | 4.0(3.8,4.3) | 125.0(114.0,134.0) | 66.8(53.4,84.7) | 20.0(13.3,23.5) | 24.5(20.5,29.0) | 66.0(50.8,75.3) |
| Z(χ2)值 | -1.623 | -1.606 | -1.015 | -0.783 | -0.490 | -0.812 | -0.214 | |
| P值 | 0.105 | 0.108 | 0.310 | 0.434 | 0.624 | 0.417 | 0.830 | |
| 组别 | 尿素氮(mmol/L) | 癌胚抗原(ng/mL) | 血清CA199(U/mL) | 血清CA125(U/mL) | 血清CA724(U/mL) | 复发转移患者数量[例(%)] | 并发症数量[例(%)] | |
| 对照组 | 5.7(4.6,6.6) | 3.2(2.6,4.7) | 17.6(7.8,30.5) | 9.9(6.3,12.1) | 2.2(0.6,5.1) | 3(7.5) | 6(16.2) | |
| 联合管理组 | 5.7(4.4,6.5) | 1.4(1.0,2.9) | 12.5(9.3,16.3) | 10.0(7.0,14.4) | 2.2(0.6,5.0) | 1(2.8) | 0 | |
| Z(χ2)值 | -0.058 | -4.653 | -1.595 | -0.271 | -0.145 | 0.165a | 3.981a | |
| P值 | 0.954 | <0.001 | 0.111 | 0.786 | 0.885 | 0.685 | 0.046 |
| 组别 | 例数 | 白细胞(×109/L) | 红细胞(×1012/L) | 血红蛋白(g/L) | 中性粒细胞百分比(%) | 丙氨酸氨基转移酶(U/L) | 天冬氨酸氨基转移酶(U/L) | ||
|---|---|---|---|---|---|---|---|---|---|
| 对照组 | 40 | 4.3(3.7,6.1) | 3.3(2.9,3.8) | 118.5(101.5,124.3) | 60.8(51.7,75.1) | 20.5(15.8,30.3) | 27.5(21.8,38.0) | ||
| 联合管理组 | 36 | 5.4(4.4,6.4) | 4.0(3.6,4.4) | 130.0(118.0,144.5) | 54.7(51.2,71.9) | 20.0(17.0,25.0) | 28.0(25.0,32.5) | ||
| Z(χ2)值 | -0.536 | -1.577 | -1.448 | -0.496 | -0.035 | -0.300 | |||
| P值 | 0.592 | 0.115 | 0.148 | 0.620 | 0.972 | 0.765 | |||
| 组别 | 肌酐(µmol/L) | 尿素氮(mmol/L) | 癌胚抗原(ng/mL) | 血清CA199 (U/mL) | 血清CA125 (U/mL) | 血清CA724 (U/mL) | 复发转移患者数量[例(%)] | 并发症数量[例(%)] | 死亡患者数量[例(%)] |
| 对照组 | 70.5(57.8,86.0) | 5.9(5.1,8.1) | 3.8(3.0,4.4) | 13.5(6.2,29.9) | 10.2(6.9,13.6) | 1.5(0.6,3.3) | 9(22.5) | 10(25.0) | 3(7.5) |
| 联合管理组 | 62.0(54.5,75.5) | 5.5(4.8,6.1) | 2.6(1.2,3.6) | 12.5(9.0,22.5) | 9.0(7.6,12.3) | 1.4(0.7,8.3) | 2(5.6) | 2(5.6) | 1(2.8) |
| Z(χ2)值 | -0.967 | -0.282 | -3.634 | -0.722 | -1.140 | -0.363 | 4.395a | 5.388a | 0.165a |
| P值 | 0.333 | 0.778 | <0.001 | 0.470 | 0.254 | 0.717 | 0.036 | 0.020 | 0.685 |
Table 4 Comparison of the two groups of colorectal cancer patients at 6 months after surgery
| 组别 | 例数 | 白细胞(×109/L) | 红细胞(×1012/L) | 血红蛋白(g/L) | 中性粒细胞百分比(%) | 丙氨酸氨基转移酶(U/L) | 天冬氨酸氨基转移酶(U/L) | ||
|---|---|---|---|---|---|---|---|---|---|
| 对照组 | 40 | 4.3(3.7,6.1) | 3.3(2.9,3.8) | 118.5(101.5,124.3) | 60.8(51.7,75.1) | 20.5(15.8,30.3) | 27.5(21.8,38.0) | ||
| 联合管理组 | 36 | 5.4(4.4,6.4) | 4.0(3.6,4.4) | 130.0(118.0,144.5) | 54.7(51.2,71.9) | 20.0(17.0,25.0) | 28.0(25.0,32.5) | ||
| Z(χ2)值 | -0.536 | -1.577 | -1.448 | -0.496 | -0.035 | -0.300 | |||
| P值 | 0.592 | 0.115 | 0.148 | 0.620 | 0.972 | 0.765 | |||
| 组别 | 肌酐(µmol/L) | 尿素氮(mmol/L) | 癌胚抗原(ng/mL) | 血清CA199 (U/mL) | 血清CA125 (U/mL) | 血清CA724 (U/mL) | 复发转移患者数量[例(%)] | 并发症数量[例(%)] | 死亡患者数量[例(%)] |
| 对照组 | 70.5(57.8,86.0) | 5.9(5.1,8.1) | 3.8(3.0,4.4) | 13.5(6.2,29.9) | 10.2(6.9,13.6) | 1.5(0.6,3.3) | 9(22.5) | 10(25.0) | 3(7.5) |
| 联合管理组 | 62.0(54.5,75.5) | 5.5(4.8,6.1) | 2.6(1.2,3.6) | 12.5(9.0,22.5) | 9.0(7.6,12.3) | 1.4(0.7,8.3) | 2(5.6) | 2(5.6) | 1(2.8) |
| Z(χ2)值 | -0.967 | -0.282 | -3.634 | -0.722 | -1.140 | -0.363 | 4.395a | 5.388a | 0.165a |
| P值 | 0.333 | 0.778 | <0.001 | 0.470 | 0.254 | 0.717 | 0.036 | 0.020 | 0.685 |
| 组别 | 例数 | EORTC QLQ-C30评分 | SAS评分 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 术前 | 术后6个月 | 术后1年 | F值 | P值 | 术前 | 术后6个月 | 术后1年 | F值 | P值 | ||
| 对照组 | 40 | 56.36±2.57 | 44.73±3.41a | 36.98±4.65a | 265.000 | <0.001 | 51.67±6.36 | 63.56±4.72a | 72.41±5.25a | 133.149 | <0.001 |
| 联合管理组 | 36 | 55.26±3.46 | 48.74±2.16a | 42.03±1.94a | 225.233 | <0.001 | 52.74±4.17 | 60.12±6.23a | 66.49±5.67a | 56.274 | <0.001 |
| t值 | 1.537 | -5.922 | -5.952 | -0.839 | 2.650 | 4.600 | |||||
| P值 | 0.129 | <0.001 | <0.001 | 0.405 | 0.010 | <0.001 | |||||
Table 5 Comparison of quality of life and SAS scores of colorectal cancer patients before and after surgery in both groups
| 组别 | 例数 | EORTC QLQ-C30评分 | SAS评分 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 术前 | 术后6个月 | 术后1年 | F值 | P值 | 术前 | 术后6个月 | 术后1年 | F值 | P值 | ||
| 对照组 | 40 | 56.36±2.57 | 44.73±3.41a | 36.98±4.65a | 265.000 | <0.001 | 51.67±6.36 | 63.56±4.72a | 72.41±5.25a | 133.149 | <0.001 |
| 联合管理组 | 36 | 55.26±3.46 | 48.74±2.16a | 42.03±1.94a | 225.233 | <0.001 | 52.74±4.17 | 60.12±6.23a | 66.49±5.67a | 56.274 | <0.001 |
| t值 | 1.537 | -5.922 | -5.952 | -0.839 | 2.650 | 4.600 | |||||
| P值 | 0.129 | <0.001 | <0.001 | 0.405 | 0.010 | <0.001 | |||||
| [1] |
周岩冰. 我国胃肠道肿瘤围手术期加速康复外科路径管理的思考与建议[J]. 中华胃肠外科杂志,2022,25(7):568-574. DOI:10.3760/cma.j.cn441530-20220411-00140.
|
| [2] |
徐月梅,范晓圆,童可辉,等. 经皮神经调控改善100例胃肠道肿瘤术后患者胃肠功能的临床价值[J]. 中华消化杂志,2021,41(6):392-396. DOI:10.3760/cma.j.cn311367-20201204-00688.
|
| [3] |
|
| [4] | |
| [5] |
孔灿,阮利斌,杨余沙,等. 规范营养支持对胃肠道肿瘤患者围术期临床结局的影响[J]. 中国医刊,2022,57(2):177-180. DOI:10.3969/j.issn.1008-1070.2022.02.017.
|
| [6] |
李霜,张红娇,刘丽敏. 支持性心理治疗联合术前访视对胃肠道恶性肿瘤手术患者焦虑情绪及日常生活的影响[J]. 解放军预防医学杂志,2019,37(7):97-98,100.
|
| [7] |
周同,胡雁,彭健,等. 多学科协作的心理社会干预对胃肠道恶性肿瘤化疗患者心理痛苦、焦虑及抑郁情绪的影响[J]. 复旦学报(医学版),2020,47(6):875-881,898. DOI:10.3969/j.issn.1672-8467.2020.06.012.
|
| [8] |
郭金宝,管步高,万本海,等. 胃肠吻合口漏的诊断、治疗及预防进展[J]. 医学理论与实践,2021,34(22):3896-3898. DOI:10.19381/j.issn.1001-7585.2021.22.012.
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
郑惠娟,刘宁,邵娜. 胃肠肿瘤手术中预防切口感染持续质量改进的可行性及其危险因素分析[J]. 解放军预防医学杂志,2019,37(2):46-47,50.
|
| [13] |
言赟,孙静. 胃肠肿瘤手术住院患者营养风险及术后感染的相关性探讨[J]. 中国肿瘤临床与康复,2021,28(6):764-768. DOI:10.13455/j.cnki.cjcor.2021.06.32.
|
| [14] |
徐欣怡,许勤,花红霞,等. 基于预测模型的消化道肿瘤术后疲劳风险筛查评分量表的构建与应用[J]. 中国全科医学,2020,23(14):1819-1826,1832. DOI:10.12114/j.issn.1007-9572.2019.00.793.
|
| [15] |
欧琼珊,张椿娜,傅若珊,等. 基于快速康复外科理念的多学科合作模式镇痛管理在胃肠肿瘤患者中的应用研究[J]. 中国医药科学,2020,10(5):230-233. DOI:10.3969/j.issn.2095-0616.2020.05.066.
|
| [16] |
|
| [17] |
吴星烨,张军. 胃肠间质瘤患者的全程化信息化管理[J]. 中华胃肠外科杂志,2020,23(9):858-860. DOI:10.3760/cma.j.cn.441530-20200531-00328.
|
| [18] |
吴琪,黄颖,时艳霞. 群组干预对胃肠癌术后患者出院准备及自理能力的影响[J]. 中国当代医药,2022,29(23):164-167. DOI:10.3969/j.issn.1674-4721.2022.23.043.
|
| [19] |
曹水英,郭玉青,高学军,等. 认知-心理-社会支持干预对颅内肿瘤患者术后负性情绪、应对方式及生活质量的影响[J]. 癌症进展,2020,18(13):1388-1391. DOI:10.11877/j.issn.1672-1535.2020.18.13.24.
|
| [20] |
|
| [21] |
|
| [1] | HAN Leyang, ZHENG Huixian, TIAN Yiran, TANG Haoqing, LONG Ren, LI Daihan, LIU Xiaoyun. Measuring Integrated Services for Rural Chronic Disease Patients Based on Formative Measurement Theory [J]. Chinese General Practice, 2026, 29(31): 4543-4550. |
| [2] | KUANG Li, DING Xinxin, MA Yuanzhu. Application of Motivational Interviewing in Healthcare Provider-Patient Communication for Chronic Disease Management in Primary Care: from Principles to Practice [J]. Chinese General Practice, 2026, 29(31): 4536-4542. |
| [3] | LI Xiling, ZHANG Fan, YANG Xinyue, YANG Heng. Application of Exercise Snacks in Chronic Disease Management: a Scoping Review [J]. Chinese General Practice, 2026, 29(30): 4472-4479. |
| [4] | SHI Zhiyao, GAO Yu, LIU Likun, GUO Zhi, WANG Xixing. Research Progress on Cell Pyroptosis in Colorectal Cancer Transformation and Disease Development [J]. Chinese General Practice, 2026, 29(27): 4026-4032. |
| [5] | LI Xuebo, LIU Xuan, LI Shuxing. Study on the Correlation between Chinese Healthy Dietary Pattern and Sarcopenia in Colorectal Cancer Patients [J]. Chinese General Practice, 2026, 29(26): 3805-3815. |
| [6] | XUE Cuirong, WEI Wei, WU Renyuan, XUE Yaqin, XU Huijiang, LYU Weijiang, JIANG Dandan. Prevalence and Management Status of Chronic Kidney Disease in Hypertensive and Type 2 Diabetic Populations: a Community-based Cross-sectional Study [J]. Chinese General Practice, 2026, 29(25): 3650-3654. |
| [7] | LIU Shuai, YUAN Shizhao, LIU Yan, JIA Shuoxian, ZHAO Yan, WANG Ziyi, ZHOU Chunhua, YU Jing. Evaluation of the Efficacy, Safetyand Economy of Different Amphotericin B Formulationsin Invasive Fungal Disease: a Retrospective Cohort Study [J]. Chinese General Practice, 2026, 29(21): 2967-2974. |
| [8] | CHENG Yu, HAN Shiyao, SUN Ping, XIANG Juan, YANG Hui, LI Dongze, ZHENG Li, LIAO Xiaoyang. Analysis of Socioeconomic and Demographic Challenges in Chronic Disease Management [J]. Chinese General Practice, 2026, 29(20): 2800-2807. |
| [9] | CHEN Qiulong, CHEN Jia, FANG Jing, DAI Wei, YANG Qing. Application Status and Research Progress of Observer-reported Outcome [J]. Chinese General Practice, 2026, 29(18): 2561-2570. |
| [10] | JIAO Xitong, LIU Lu, GUO Jiayue, YOU Lili. Prospects for the Application of Digital Therapy Products for Hypertension at Home and Abroad and the Implications for China [J]. Chinese General Practice, 2026, 29(10): 1354-1360. |
| [11] | LIU Dianchun, WANG Qianyun, CHEN Xiaoying, WEI Xuehan, WANG Runze, PENG Hongye, WANG Ying, XUE Xue, YANG Guoyan, XIAO Wei, LU Chunli. Construction and Prospect of a Distinctive Medical Intervention Model for Chronic Disease Management Integrating Lifestyle Medicine and Traditional Chinese Medicine [J]. Chinese General Practice, 2026, 29(07): 830-838. |
| [12] | JIANG Rui, CHANG Guangming, XU Lingling, ZHOU Yuhan, WEI Xinrui, YANG Min, YUE Lu, HUANG Lyuzhuang, WANG Yongchen. Intervention Strategies for Optimizing Chronic Disease Management in Primary Healthcare Services in China: a Perspective Based on Antifragility Development Theory [J]. Chinese General Practice, 2026, 29(01): 17-23. |
| [13] | YAN Xinfeng, YU Chuanning, CAO Sijing, YIN Daogen, SHAN Xiaotao, WANG Yijing, XIE Pei, ZHAO Jie, YANG Weiyi, LIU Gang, HAN Xinxin. Digitally Enabled Generalist-Specialist Collaborative Care on Chronic Care Management of Community under the National Basic Public Health Service: Practical Exploration and Early Achievement [J]. Chinese General Practice, 2025, 28(31): 3897-3903. |
| [14] | YAN Fanghong, PENG Guotian, ZHANG Guoli, SUN Ruiyi, MA Yuxia, HAN Lin. Matching Analysis of the Content of Chronic Disease Management for the Elderly in Medical Union: Based on the Perspective of "Guidance-Practice-Need" [J]. Chinese General Practice, 2025, 28(25): 3119-3126,3136. |
| [15] | WANG Xiaolin, LI Qiuyue, ZHOU Yanjun, ZHANG Jinhui, LIANG Tao. Incidence and Risk of Cardiovascular Toxicity with Fruquintinib in Metastatic Colorectal Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(23): 2934-2940. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||